Ilaris

From WikiMD.org
Jump to navigation Jump to search

Ilaris

Ilaris (pronounced /ɪˈlærɪs/), also known as canakinumab, is a monoclonal antibody designed for the treatment of various autoinflammatory syndromes. It is produced by Novartis, a Swiss multinational pharmaceutical company.

Etymology

The name "Ilaris" is a brand name given by Novartis. The generic name "canakinumab" follows the INN guidelines for monoclonal antibodies, with the suffix "-mab" indicating it is a monoclonal antibody, and "kin" referring to its target, interleukin-1 beta.

Usage

Ilaris is used to treat a number of conditions, including CAPS, SJIA, AOSD, and Gouty arthritis. It works by blocking the action of interleukin-1 beta, a part of the immune system that can cause inflammation and other symptoms in these conditions.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski